IDYA · NASDAQ

IDEAYA Biosciences, Inc.

Q: How do I get IDYA news from the API?

Call GET /v1/news?tickers=IDYA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

$33.53 +0.66 (+2.01%)

Company overview

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $3.2B
Employees: 131
Headquarters: South San Francisco, CA
Website: ideayabio.com
CEO: Yujiro S. Hata
Listed: May 23, 2019
P/E: -21.22
Dividend yield: 0.00%

Company financials

Revenue: $225M
Gross profit: $224M
Operating income: -$183M
EBITDA: -$179M
Net income: -$140M
EPS: -$1.58
Total assets: $1B
Total debt: $28.6M
Gross margin: 99.49%
Net margin: -62.17%
Earnings yield: -4.71%

Revenue segmentation

By product (FY 2025)

By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

IDYA 1D NASDAQ O34.11H34.51L32.76C32.87-1.09 (-3.21%)Vol434.76K

News

Ticker	Type	Headline	Source	Published
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of...	PR Newswire	Oct 30, 6:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Stock news	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?	Zacks Investment Research	Oct 27, 11:01:02 AM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas IDEAYA Biosciences, In.	PR Newswire	Oct 23, 6:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma IDEAYA Bioscience.	PR Newswire	Oct 19, 6:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Stock news	IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock	Defense World	Oct 11, 5:38:58 AM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development	PR Newswire	Sep 28, 6:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	PR Newswire	Sep 25, 6:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Stock news	IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript	Seeking Alpha	Sep 10, 5:37:11 PM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma	PR Newswire	Sep 9, 6:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences	PRNewsWire	Sep 1, 6:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Stock news	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GuruFocus	Aug 28, 7:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Stock news	Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform	Seeking Alpha	Aug 25, 9:13:35 AM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer	PRNewsWire	Aug 19, 6:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update	PRNewsWire	Aug 4, 6:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs	PRNewsWire	Jul 17, 9:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Stock news	IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late	GuruFocus	Jun 1, 12:00:00 PM ET
IDYAIDEAYA Biosciences, Inc.	Press release	IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO	PRNewsWire	Jun 1, 11:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Stock news	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GuruFocus	May 29, 7:00:00 AM ET
IDYAIDEAYA Biosciences, Inc.	Stock news	IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit	MarketBeat	May 26, 7:04:00 PM ET
IDYAIDEAYA Biosciences, Inc.	Stock news	IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing	MarketBeat	May 25, 7:07:58 AM ET

FAQ

Questions about IDEAYA Biosciences, Inc.

What does IDEAYA Biosciences, Inc. do?

What is IDYA's market cap?

IDEAYA Biosciences, Inc. (IDYA) is a listed stock with a live quote. The latest market cap on this page is $3.2B.

Where is IDEAYA Biosciences, Inc. headquartered?

IDEAYA Biosciences, Inc. is headquartered in South San Francisco, CA.

How do I get IDYA news from the API?

Call GET /v1/news?tickers=IDYA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does IDYA news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IDYA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the IDYA price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs